Search Results 1151-1160 of 19025 for Neutrophil

1. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 (enrollment by invitation only) - Mayo Clinic

   Presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (ANC) less than 2000 mm3, aspartate aminotransferase ...

2. S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer - Mayo Clinic

   Absolute Neutrophil Count ≥ 1,500/mL. Hemoglobin ≥ 9 g/dL. Platelet count ≥ 100,000/mL. Bilirubin ≤ 1.5 mg/dL (≤ 3.0 mg/dL if due to Gilbert syndrome) ...

3. A Study to Evaluate Pembrolizumab with Standard Therapy to Treat Newly-diagnosed Glioblastoma - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1500/mm^3;; Platelet count ≥ 100,000/mm^3;; Hemoglobin ≥ 9.0 g/dL without transfusion or EPO dependency (≤7 days prior ...

4. A Study to Evaluate the Safety and Effectiveness of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients - Mayo Clinic

   Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts, at screening unless resulting from underlying ...

5. CNS Tumors With Latent Residual Disease To Guide Individualized Therapies - Mayo Clinic

   Absolute neutrophil count (ANC) ≥1500/mm. Platelet count ≥100,000/mm3 (without transfusion ≤7 days preceding lab assessment). Alanine aminotransferase (ALT) ...

6. GATE1: A Multicenter Phase II Study Of Pirtobrutinib, Rituximab And Venetoclax Combination Therapy For Patients With Previously Untreated Mantle Cell Lymphoma - Mayo Clinic

   * Absolute neutrophil count (ANC) ≥ 1000/µL without growth factor support * Platelet count ≥ 75,000/µL without transfusion support (≥ 50,000/µL if there ...

7. Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

8. Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer - Mayo Clinic

   Absolute neutrophil count ≥ 1,500/mcL. Platelets ≥ 150,000/mcL. Hemoglobin ≥ 10 g/dL. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) ...

9. Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) - Mayo Clinic

   Bloodwork must be collected within 10 days prior to the start of study treatment. - Hematological --- Absolute neutrophil count (ANC) ≥1500/µL - Platelets ...

10. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery - Mayo Clinic

    Absolute neutrophil count (ANC) >= 1.5 x 10^9/L; Hemoglobin >= 10 g/dL; Platelets >= 100 x 10^9/L; Total serum bilirubin =< institutional upper limit of normal ...